Dr. Kelly

W. Kevin Kelly, DO

Contact Dr. Kelly

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Effect of docetaxel on safety and efficacy of radium-223
  2. Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray
  3. Targeting epigenetics for the treatment of prostate cancer: Recent progress and future directions
  4. Prostate cancer biomarker: A key field to explore
  5. C-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
  6. Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer
  7. An internet intervention for management of uncertainty during active surveillance for prostate cancer
  8. New therapies for castration-resistant prostate cancer: Efficacy and safety
  9. Epothilones in prostate cancer
  10. Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancer
  11. The needs for men undergoing active surveillance (AS) for prostate cancer: Results of a focus group study
  12. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
  13. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials
  14. Redefining hormone resistance in prostate cancer
  15. Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy
  16. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration-resistant prostate cancer
  17. Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer
  18. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
  19. TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality
  20. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer